Bharat Biotech has commenced export of its Covid-19 vaccine—Covaxin, the company tweeted.

It also said that long pending orders have been executed during November to be further expanded during the following months. With the number of countries that have granted Emergency Use Approvals for Covaxin, increasing exports to additional countries will also commence from December.

Earlier this month, The World Health Organization (WHO) issued an emergency use listing (EUL) for Covaxin (developed by Bharat Biotech), adding to a growing portfolio of vaccines validated by WHO for the prevention of Covid-19 caused by SARS-CoV-2.

The vaccine is developed using Whole-Virion Inactivated Vero Cell derived platform technology. Inactivated vaccines do not replicate and are therefore unlikely to revert and cause pathological effects. They contain dead virus, incapable of infecting people but still able to instruct the immune system to mount a defensive reaction against an infection.